CRISPR Therapeutics (CRSP) PT Raised to $64 at Barclays
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $59.50 +2.37%
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Barclays analyst Gena Wang raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $64.00 (from $61.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
- Sinclair Broadcasting (SBGI) PT Raised to $15 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
